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ABSTRACT
Breast cancer is one of the health problems in the world. In Indonesia, it was highest 
prevalence of cancer in 2018. CD44, a non-kinase transmembrane glycoprotein, 
plays an important role in cancer development and progression. It is responsible 
for mediating of the adhesion between adjacent cells andal so between cells and 
the extracellular matrix. The aim of study was to investigate the relationship 
between the CD44 expressionand histopathological grading, metastasis, overall 
survival (OS) as well as disease free survival (DFS) in breast cancer patients.This 
was a retrospective cross sectional study using data on medical records of breast 
cancer cases at Dr. Wahidin Sudirohusodo General Hospital, Makasar from 2016 
to 2018. Examination of CD44 expression were performed from paraffin block 
samples. Data of the CD44 expression and medical records obtained were then 
presented in tables and statistically analyzed using chi-squared and Kaplan–Meier 
survival analysis. No significantly relationship between the CD44 expression 
and histopathological grading was reported (p>0.05). However, significantly 
relationship between the CD44 expression and metastasis war reported (p<0.01). 
Patients with metastasis having high CD44 expression was significantly higher 
(90%) than those patients without metastasis (60%) (p<0.01). No significantly 
relationship between the CD44 expression and OS or DFS was reported (p>0.05). In 
conclusion, there is relationship between CD44 expression and metastasis in the 
breast cancer patients. However, there is norelationship between CD44 expression 
and histopathological grading, OS as well as DFS. 
ABSTRAK
Kanker payudara merupakan salah satu masalah kesehatan di dunia. Di 
Indonesia, prevalensi kanker payudara paling tinggi pada 2018. CD44, 
glikoprotein transmembran non kinase, berperan penting dalam perkembangan 
dan progresivitas kanker. CD44 berperan dalam proses adisi antara sel yang 
berdekatan dan juga antara sel dan matrik ekstra selular. Penelitian ini bertujuan 
untuk mengkaji hubungan antara ekspresi CD44 dan nilai gambaran histopatologi, 
metastasis, keseluruhan kelangsungan hidup (OS), kelansungan hidup bebas 
penyakit (DFS) pada pasien kanker payudara. Ini adalah penelitian potong 
lintang retrospektif menggunakan data rekam medis kasus kanker payudara di 
Rumah Sakit Umum Dr. Wahidin Sudirohusodo, Makasar dari tahun 2016-2018. 
Pemeriksaan ekspresi CD44 dilakukan dari sampel blok parafin. Data ekspresi 
CD44 dan rekam medis yang diperoleh selanjutnya dipresentasikan dalam table 
dan dianalisis secara statistic menggunakan chi-square dan analisis keseluruhan 
hidup Kaplan-Meier. Tidak terdapat hubungan nyata antara ekspresi CD44 dan 
nilai gambaran histopatologi (p>0,05). Namun demikian, terdapat hubungan nyata 
antara ekspresi CD44 dan metastasis (p<0,01). Pasien metastasis yang mempunyai 
eskpresi CD44 tinggi (90%) lebih besar secara nyata dibandingkan pasien tanpa 
metastasis (60%). Tidak ada hubungan nyata antara ekspresi CD44 dan OS 
atau DFS (p>0,05). Dapat disimpulkan ada hubungan antara ekspresi CD44 dan 
metastasis pada pasien kanker payudara. Namun demikian tidak ada hubungan 
antara ekspresi CD44 dan nilai gambaran histopatologi, OS dan DFS. 
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INTRODUCTION
Breast cancer is one of the health 
problems in the world. It is the he most 
commonly occurring cancer in women 
and the second most common cancer 
overall. According to the Global Cancer 
Statistics 2018, 18.1 million new cancer 
cases were reported (17.0 million 
excluding nonmelanoma skin cancer) 
and 9.6 million cancer deaths (9.5 million 
excluding nonmelanoma skin cancer) in 
2018. In both sexes combined, lung cancer 
is the most commonly diagnosed cancer 
(11.6% of the total cases) and the leading 
cause of cancer death (18.4% of the 
total cancer deaths), closely followed by 
female breast cancer (11.6%). According 
to the American Cancer Society (ACS) 
in 2012, breast cancer is the second 
leading cause of death in women (14%) 
after lung cancer (26%) in the United 
States.1 In Indonesia, based on Basic 
Health Research (Riset Kesehatan Dasar/
Riskesdas) data in 2018, breast cancer 
is the highest prevalence of cancer in 
Indonesia that is suffered 58,256 patients 
or 16.7% from 348.809 cases.2 Hospital 
based study conducted in Dr. Wahidin 
Sudirohusodo General Hospital, Makasar 
reported during a period 2008-2012 as 
much as 1,497 patients (299 patients a 
year) were diagnosed as breast cancer. 
About 39.4% of them aged between 40-
49 years.3
In the developed countries, more 
breast cancer is diagnosed in early stages.4 
However, in the developing countries 
including Indonesia it is diagnoses in 
late stages. In Padang, the percentage 
of   breast  cancer  patients  with stage 
IIIA and IIIB were 43.4 and 14.3%, 
respectively.4 In West Jakarta, it was 
reported the most of frequent of female 
breast cancer were in 45-49 years old, not 
other specific location subtopography 
(81.5%), the histopathology type was 
ductal and lobular neoplasm (51.8%), in 
stage III (44%), and with metastases to 
bone (34%).5
Various studies have proven the 
important role of tumor markers 
in assessing disease progression, 
monitoring therapy, recurrence and 
prognostic factors in malignancies.6-8 
CD44, a non-kinase transmembrane 
glycoprotein, plays an important role in 
cancer  development  and  progression. 
It is responsible for mediating of the 
adhesion between adjacent cells and 
also between cells and the extracellular 
matrix. The CD44 is associated with 
prognostic factors in breast cancer.9,10 
The adhesion cells play an important 
role to construc the basic form of 
normal breast histology that are 
important for maintaining tissue 
integrity. This disruption of adhesion 
relationship causes  loss of network 
architecture which is a sign of malignant 
transformation. This study aimed to 
evaluate the relationship between CD44 
expression of histopathological grading, 
metastasis, overall survival (OS) and 
disease free survival (DFS).
MATERIALS AND METHODS
Design and subject
This was a retrospective cross 
sectional study using data on medical 
records of breast cancer cases at Dr. 
Wahidin Sudirohusodo General Hospital, 
Makasar from 2016 to 2018 who met the 
inclusion and exclusion criteria. The 
inclusion criteria were women with 
breast cancer who have been proven by 
histopathological examination, breast 
cancer patients with PA results showing 
histopathological grading by Nottingham 
Modification of Bloom Richardson 
System, patients with metastatic breast 
cancer evidenced by radiological 
examination (photo thorax, ultrasound, 
CT scan or MRI), and patient were 
willing to be involved in this study. The 
exclusion criteria were breast cancer 
patients with biopsy results do not show 
histopathological grading, and suffer 
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from other types of cancer (eg ovarian, 
liver, lung cancer). Subjects were 
selected using a randomized purposive 
sampling method taking members of the 
population. Sixty subjects who met the 
inclusion and exclusion criteria were 
involved in this study.
CD44 expression examination
The paraffin block sample was 
examined for CD44 expression using 
CD44 antibody (DF1485, Novocastra 
Laboratories Ltd., dilution 1:100) 
then count the percentage of positive 
cells and their intensity visually 
using a comparison light microscope. 
Immunostained samples were evaluated 
blind by one pathologist. CD44 was 
stained in cell membrane, with score 
0 if < 10% positive tumour cells; 1 if 10-
25%; 2 if 25-50%; and 3 if > 50%. Intensity 
was scored as 0 if unstained, 1 if weakly 
stained, 2 if intermediate, and 3 if strong. 
Interpretation of CD44 staining was 
determined based on multiplication of 
the percentage of positive cells and the 
intensity of staining. CD44 was scored as 
low if (-until +4) and high (+5 until +9). 
Data of CD44 expression and medical 
records were then processed, analyzed 
with chi square and presented in tables, 
graphs and narratives. This study was 
approved by the Joint Ethics Committee 
of Faculty of Medicine Hasanuddin 
University, Hasanuddin University 




Data were presented as frequency 
distribution or percentage. Chi Square 
test was used to evaluate the relationship 
between histopathological grading 
or metastasis with CD44 expression. 
Kaplan–Meiersurvival analysis was 
applied to evaluate relationship of 
overall survival (OS) or disease free 
survival (DFS) with CD44expression.
RESULT
The subjects characteristics of the 
study are presented in the TABLE 1. The 
largest number of subject saged between 
40-49 years (63.7%) with moderate 
grading (55.0%), not metastatic (50.0%), 
multiple metastatic sites (15%), no DFS 
status (56.7%), and no OS status (60.0%). 
The subjects with high CD44 levels was 
75.0% and low CD44 levels was 25.0%.
TABLE1. Frequency distribution of research subjects 
characteristics
Characteristics Number Percentage (%)
Age (year old)
•	 <40 12 20.0
•	 40-49 38 63.7
•	 50-59 14 23.3
•	 60-69 6 10.0
•	 >= 70 0 0.0
Hispathological grade
•	 Low 4 6.6
•	 Moderate 33 55.0
•	 High 23 23.6
Metastatic amount
•	 Multiple 9 15.0
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•	 Single 21 35.0
•	 None 30 50.0
Metastatic site 
•	 Bone 3 5.0
•	 Lung 14 23.4
•	 Liver 2 3.3
•	 Brain 2 3.3
•	 None 30 50.0
•	 Multiple 9 15.0
DFS status
•	 Yes 26 43.3
•	 No 34 56.7
OS status
•	 Yes 24 40.0
•	 No 36 60.0
CD44 expression
•	 High 45 75.0
•	 Low 15 25.0
TABLE 2 shows the relationship 
between CD44 expression with 
histopathological grading of the 
breast cancer  patients.  The  high 
CD44 expression of patients with high, 
moderate, and low histopathological 
gradingwere 81.0%, 75.8% and 
50.0%, respectively. No significantly 
relationship between CD44 expression 
with  histopathological  grading.
TABLE  2. Relationship between CD44 expression with histopathological grading




High 4 (19.0) 17 (81.0) 21 (100.0)
Moderate 8 (24.2) 25 (75.8) 33 (100.0)
Low 3 (50.0) 3 (50.0) 6 (100.0)
Amount 15 (25.0) 45 (75.0) 60 (100.0)
Chi square test (p=0.300)
TABLE 3 shows the relationship 
between  CD44  expression  with 
metastasis in breast cancer patients. 
Patients with metastasis having high 
CD44 expression was significantly 
higher  (90%) than those patients 
without metastasis (60%) (p<0.01). A 
significantly relationship between the 
CD44 expression and metastasis war 
observed (p<0.01).
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CD44 expression [n (%)]
Total
Low High
Yes 3 (10.0) 27 (90.0) 30 (100.0)
No 12 (40.0) 18 (60.0) 30 (100.0)
Total 15 (25.0) 45 (75.0) 60 (100.0)
Chi square test (p=0.01)
FIGURE 1 shows the OS analysis 
using median with following up to 3 
years for survival that could be divided 
into two groups. From month 0 to 5th 
month, the survival rate for OS with low 
and high CD44 expressions was similar 
with OS value of 75%. Decrease in 35% 
survival rate of patients with high CD44 
expression was observed on the 10th 
month, where as for patients with low 
CD44 expression on the 17th month. 
Furthermore, the patients with high 
CD44 expression showed a progressive 
decrease in survival rate from month to 
month. In the 20th month, the survival 
rate decreased to be <15% and then 
0-5% in the 25th month. The decrease in 
survival rate of patients with low CD44 
expression in the 20th, 25th, 30th, and 
40th moths were 20%, 15-20%, 10% and 
5-10%, respectively. No significantly 
relationship between CD44 expression 
and OS was observed (p>0.05).
FIGURE1. Kaplan–Meier curve relationship of OS according to CD44 
expression
248
J Med Sci, Volume 52, Number 3, 2020, July: 243-250
FIGURE 2 shows the prediction test 
of patient’s survival with low and high 
CD44 expressions using Kaplan-Meier 
analysis. The DFS degree of patients with 
high CD44 expression in the 5th, 10th, 20th 
were 60%, 20% and 5%, respectively. 
The longer the patients suffer, the 
more decreased the patient’s ability to 
respond to the effects of the disease. The 
DFS degree of patients with low CD44 
expression in the 5th, 10th, 20th were 65%, 
40% and 20%, respectively. Although 
the DFS degree in low CD44 expression 
group was higher than that in high CD44 
expression group, it was not significantly 
different.
FIGURE 2. Kaplan–Meier curve relationship of DFS according to CD44 
expression
FIGURE 3 shows the CD44 
immunohistochemical staining of breast 
cancer tissues. Low CD44 expression 
was considered if less than 50%of the 
positive cells membrane or cytoplasmic 
were observed. High CD44 expression 
was considered if more than 50% of the 
positive cells membrane or cytoplasmic 
were observed.
A B
FIGURE 3. Imunohistochemistry CD44 Expression stain (scale 400x). A) negative or 
low expression; B) positive or high expression.
249
Syaifudin A, et al, Correlation between CD44...
DISCUSSION
CD44 is involved in multiple 
physiological  and  pathological 
processes, such as angiogenesis, 
cell adhesion, inflammation, and 
cancer development. It is involved in 
tumorigenesis and metastasis in many 
cancer types such as colon, bladder, and 
gastric cancers. However, the role of the 
CD44 in breast cancer remains unclear.11 
Previous studies concerning the role of 
CD44 in tumorigenesis and metastasis 
gave different results.
In this study, no significantly 
relationship between the CD44 
expression and histopathological grading 
was reported. The relationship between 
CD44 expression and histopathological 
grading has been reported in the 
previous studies with different results. 
Farida et al.12 and Jang et al.13 reported 
that CD44 expression is not correlated 
with histopathological grading in 
breast cancer. Otherwise, Moansoori et 
al.14 and McFarlane et al.15 reported a 
significant positive correlation between 
CD44 expression with histological grade. 
Breast cancer samples with advance 
histological grade also had higher CD44 
expression. In addition, Qiao et al.16 
also reported that CD44v6, a variant 
isoform of CD44, is associated with 
histopathological grade.
A positive significantly relationship 
between the CD44 expression and 
metastasis was reported in this study. 
Breast cancer patients with metastasis 
have high CD44 expression (90%) higher 
than those patients without metastasis 
(60%). Studies concerning the role of 
CD44 in tumorigenesis and metastasis 
in many cancer types including breast 
cancers have been conducted. Qiao et 
al.16 reported that CD44v6 expression 
is significantly associated with poor 
prognosis, histological grade, and 
lymph node metastasis in breast cancer 
patients, especially among Asian 
patients. Moreover, McFarlane et al.15 
also reported that CD44 expressionis 
associated with metastasis-related 
phenotype.
Kaplan-Meier analysis revealed 
that no significantly relationship 
between CD44 expression and OS as 
well as DFS were observed in this 
study (p>0.05). Previous studies have 
been reported with different results. 
McFarlane et al.15 reported that high 
CD44 expression correlated with the 
reduced DFS in lymph node-positive 
patients and patients with large tumor 
size. Furthermore, the correlation 
between CD44 overexpression and the 
poor OS rate(pooled OR =1.27, 95%CI: 
1.04–1.55, Cochran’s Q test p=0.505, and 
I2 =0.0%) was reported. However, CD44 
expression was not associated with the 
RFS rate (pooled OR=1.04, 95% CI:0.89-
1.23, Cochran’s Q test p=0.417, and I2 
=2.4%).11
CONCLUSION
In conclusion, there is a significant 
correlation between high CD44 
expression and single or multiple 
metastatic of breast cancer patients 
indicating it can be used for metastatic 
prognostic factor. However, there is 
no significant correlation between 
CD44 expression and histopathological 
grading, OS and DFS.
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